Levi & Korsinsky Alerts Pacira BioSciences Investors of Class Action Lawsuit and Deadlines
Class Action Lawsuit Notification for Pacira BioSciences Investors
Levi & Korsinsky, LLP has alerted investors of Pacira BioSciences, Inc. (NASDAQ: PCRX) regarding a class action securities lawsuit. This legal action is aimed at recuperating losses for shareholders affected by purported securities fraud that occurred between August 2, 2023, and August 8, 2024.
Understanding the Class Action
The lawsuit was initiated in response to critical information released by Pacira that impacted its stock valuation precipitously. Specifically, on August 9, 2024, the Company announced that its patent, U.S. Patent No. 11,033,495, was deemed invalid in a court ruling. This patent, crucial for Exparel, accounts for approximately 80% of Pacira's revenue. Following this announcement, Pacira's stock plummeted from $22.36 to a low of $11.70, marking a startling decline of over 47% in a single day.
This drastic drop raised alarms among investors, prompting calls for accountability and transparency from the company. Those who have recorded losses during the specified timeframe are invited to contact Levi & Korsinsky to pursue compensation.
Key Details of the Case
The class action lawsuit seeks to address grievances from investors who sustained losses attributable to the alleged securities fraud. In a statement, Levi & Korsinsky emphasized the importance for affected shareholders to act quickly, as they have until March 14, 2025, to request appointment as lead plaintiffs in the case. Notably, participation in the case does not mandate serving in this capacity, allowing shareholders to still share in any potential recovery.
No Out-of-Pocket Fees
Levi & Korsinsky assures potential class members that they may be entitled to compensation without any out-of-pocket costs or fees. There is no financial obligation or hidden costs associated with joining the class action, making it more accessible for investors to seek justice.
Why Levi & Korsinsky?
With over two decades of experience in securities litigation, Levi & Korsinsky has a strong track record, with hundreds of millions of dollars secured for shareholders in previous cases. The firm is recognized as one of the leading securities litigation firms in the United States, consistently ranking in ISS Securities Class Action Services' Top 50 Report. Their battle-tested team of over 70 professionals is committed to addressing complex litigation challenges and advocating for investor rights.
If you believe you were affected by the events surrounding Pacira BioSciences, now is the time to act. Investors can reach out directly to Joseph E. Levi, Esq., or visit the firm’s website for more details on how to participate in this class action.
Contact Information
- - Levi & Korsinsky, LLP
New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500
Investors who seek justice and recovery are encouraged to take steps now, as the deadline for action is rapidly approaching.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.